Organoid intelligence and biocomputing advances: Current steps and future directions

The paper poses the question of how organoid intelligence (OI) can transform biocomputing and biomedical research while remaining ethically and legally responsible. It frames OI as a convergence of advances in human stem cells and brain microphysiological systems that enable brain organoids to mimic human neural structure and function. Motivated by the human brain’s extreme energy efficiency (~20 W) relative to modern supercomputers (~10 MW), the review explores OI as a pathway to sustainable, high-efficiency computation and improved disease modeling and drug discovery. The introduction also emphasizes the complementary strengths of biological and digital computation, and argues for government engagement to fund innovation, ensure equitable access, and establish regulatory frameworks that safeguard ethics and data privacy. The goal is to synthesize current steps and future directions for integrating OI into computing, healthcare, and policy.

The review synthesizes a broad, multidisciplinary literature spanning neuroscience, stem-cell biology, bioengineering, AI, ethics, and law. Key strands include: (1) Foundational OI and biocomputing advances: progress in generating region-specific brain organoids and assembloids; microelectrode interfaces such as shell MEAs; microfluidic organ-on-chip systems; and computational modeling for growth and response prediction (Lancaster et al., 2013; Kirihara et al., 2019; Huang et al., 2022; Jacob et al., 2021; Smirnova et al., 2023). (2) Demonstrations of synthetic biological intelligence: DishBrain shows in vitro neuronal networks exhibiting goal-directed adaptation under closed-loop sensory feedback within a game environment (Kagan et al., 2022). (3) Training and readout paradigms: controlled patterned stimulation (electrical, optical, chemical) to induce plasticity, with quantification via electrophysiology (LTP, synchronization indices), resting-state connectivity analysis, and optical imaging (two-photon calcium imaging); AI/ML for real-time, high-throughput analysis (Kreitmair, 2023; Smirnova et al., 2023; Niikawa et al., 2022). (4) Ethical, legal, and social implications (ELSI): the Baltimore Declaration articulates principles for responsible OI development; debates on consciousness, moral status, donor consent, data privacy, and governance frameworks are surveyed across jurisdictions (Hartung et al., 2023; Farahany et al., 2018; Lavazza and Massimini, 2018; Mollaki, 2021; Pichl et al., 2023). (5) Applications and translational promise: personalized medicine, drug toxicity testing, developmental modeling, multi-omics profiling, imaging-driven analytics, and integration with AI pipelines (Figures 1–2 workflows). Overall, the literature indicates rapid technical maturation coupled with active ethical and regulatory discourse.

As a mini-review, the article does not present original experimental methods; instead, it consolidates methodological approaches used in OI research and biocomputing interfaces: (1) Organoid generation and maturation: deriving brain/neural organoids from patient iPSCs; cultivating in organ-on-chip microenvironments that recapitulate physiological cues; adding non-neural cell types (e.g., endothelial cells, microglia) and perfusion for vascularization and maturation; developing co-cultures, connectoids, and region-specific assembloids. (2) Interfacing and stimulation: integrating organoids with multielectrode arrays (shell MEAs and planar MEAs) for bidirectional electrical communication; applying controlled stimuli—electrical fields, optogenetic light patterns, and neurotransmitter delivery—for training and input encoding. (3) Readouts and analytics: electrophysiological monitoring of synaptic plasticity and network dynamics (LTP, synchronization indices, resting-state connectivity); high-resolution optical imaging (e.g., two-photon calcium imaging) to track spatiotemporal activity; multi-omics assays to profile heterogeneity and maturation states; AI/ML pipelines for real-time, high-throughput analysis and mapping organoid responses to human brain functions. (4) Computational modeling: in silico models to predict organoid growth, network development, and response under varying microenvironmental and stimulation conditions; ML models trained on organoid and human data to classify developmental phases, support drug toxicity modeling, and guide therapeutic selection. (5) Standardization and reproducibility: calls for harmonized protocols to control stimulus parameters, quantify variability, and benchmark learning-like phenomena across labs; incorporation of dynamic consent systems and data governance to support ethically compliant data lifecycle management. These methodological elements constitute the current technical toolbox enabling OI-based computation, learning quantification, and biomedical applications.

• OI offers substantial promise for sustainable, energy-efficient computation inspired by the brain’s ~20 W power use versus ~10 MW for supercomputers, suggesting orders-of-magnitude efficiency gains for certain tasks. - Brain organoids, integrated with MEAs, microfluidics, and AI, can exhibit adaptive, task-relevant activity patterns, supporting the concept of synthetic biological intelligence (e.g., DishBrain’s self-organized, goal-directed behavior under closed-loop feedback). - Practical workflows are emerging: (1) drug toxicity testing with model-based selection; (2) training ML models using organoid and human data; (3) multi-omics to resolve organoid heterogeneity; (4) imaging-driven segmentation and computational modeling to quantify structure-function relationships. - Training paradigms using electrical, optical, and chemical stimulation can induce measurable plasticity; learning-like behavior may be quantified through electrophysiological signatures and imaging-derived activity patterns. - The Baltimore Declaration provides a foundational ethical framework emphasizing standardization, governance, public engagement, and international coordination to guide responsible OI development. - Key application domains include personalized medicine (patient-derived organoids), disease modeling (especially neurodegeneration), drug discovery and toxicity testing, human development modeling, and hybrid bio-digital computing. - Major risks and needs identified: establishing standardized protocols for reproducibility and scalability; addressing data privacy, IP, and potential misuse; clarifying moral status and consent frameworks as organoids gain complexity; and harmonizing international regulations.

The review argues that leveraging the intrinsic computational dynamics of brain organoids, when coupled with MEAs, microfluidics, and AI, can address the dual challenge of scaling computational efficiency and improving translational biomedical research. Demonstrations such as DishBrain indicate that neuronal cultures can learn and adapt under structured feedback, supporting OI’s feasibility for certain classes of computations and control tasks. In biomedicine, organoid-based workflows enable more physiologically relevant disease models, improved drug toxicity assessment, and developmentally informed ML models, potentially enhancing predictive accuracy and personalization. The ethical and policy frameworks, notably the Baltimore Declaration, directly address the central research question by outlining principles for guiding OI’s advancement while mitigating concerns about consciousness, donor rights, data governance, and equitable access. The discussion highlights that meaningful progress will depend on standardization, interdisciplinary collaboration, and iterative governance tuned to empirical developments (e.g., learning quantification and functional maturity). Thus, the field’s trajectory integrates technical maturation with proactive ELSI engagement to ensure that OI’s benefits are realized responsibly.

Biocomputing through organoid intelligence sits at a pivotal interface between biology and computation, with potential to revolutionize personalized medicine, AI-driven diagnostics, and therapeutic discovery while advancing sustainable computing paradigms. By combining organoid models with electrophysiology, microfluidics, and AI/ML, OI can deliver deeper insights into human biology and enable new classes of bio-digital systems. The review underscores the need for ethical diligence, public dialogue, and robust regulatory oversight, drawing on frameworks like the Baltimore Declaration to align innovation with societal values. Future research should prioritize: (1) standardized training and measurement protocols to rigorously quantify learning-like phenomena; (2) scalable culture and interfacing technologies (vascularization, perfusion, advanced MEAs); (3) integrative multi-omics and imaging for precise phenotyping; (4) privacy-preserving, consent-aware data infrastructures; and (5) international coordination of governance to harmonize ethical norms and accelerate responsible translation.

As a mini-review, the article synthesizes existing literature without presenting new empirical datasets, so conclusions rely on reported findings and may reflect publication biases. Quantitative evidence for robust, generalizable learning or task performance in organoid systems is still emergent, and standardized protocols for stimulation, readout, and benchmarking are not yet widely adopted, limiting reproducibility and cross-study comparability. Ethical, legal, and regulatory frameworks remain incomplete and heterogeneous across jurisdictions, complicating translation and international collaboration. Technical constraints—including organoid maturation, vascularization, scale, stability, and long-term viability—pose challenges for both computation and biomedical applications. Data privacy, IP ownership, and potential misuse add further uncertainty that may affect generalizability and deployment.